FDA Grants Orphan Drug Designation to Aptose Biosciences for CG’806 in Acute Myeloid Leukemia
December 26, 2017 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 26, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Meed Partners with Jumio to Improve Remote Identity Verification, KYC Compliance and Coverage for Its Global Rollout
December 20, 2017 08:00 ET
|
Jumio Corp.
PALO ALTO, Calif., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Jumio, the creator of Netverify® identity verification solutions, announced a partnership with Meed, a GlobeOne Company and Santa Monica-based...
Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at Ash Annual Meeting
December 12, 2017 07:00 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) "Cyclacel" or the "Company"), a biopharmaceutical company developing oral...
OHSU and Aptose Present CG’806 Preclinical Data at ASH 59th Annual Meeting
December 11, 2017 16:04 ET
|
Aptose Biosciences, Inc.
PORTLAND, Ore. and SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- The OHSU Knight Cancer Institute and Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical...
Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition
December 07, 2017 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production...
Finom Blockchain Corp Announces Reg D Tokenized Equity Offering
December 04, 2017 07:45 ET
|
Finom
TEUFEN, Switzerland, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Financial blockchain corporation Finom AG today announced the launch of its $101 million tokenized equity offering to be executed pursuant to...
Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting
November 01, 2017 09:02 ET
|
Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell...
Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML
October 28, 2017 12:30 ET
|
Kura Oncology, Inc.
NPM1 and DNMT3A-mutants comprise approximately 45% of AML patientsMenin-MLL complex appears to be central node in epigenetic dysregulation giving rise to AML SAN DIEGO, Oct. 28, 2017 (GLOBE...
Melissa Demonstrates Comprehensive Global Intelligence Tools at Federal ID Forum
September 06, 2017 08:00 ET
|
Melissa
RANCHO SANTA MARGARITA, CA--(Marketwired - September 06, 2017) - Melissa, a leading provider of global contact data quality and identity verification solutions, today announced its comprehensive...
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2017 Financial Results
August 15, 2017 07:00 ET
|
Onconova Therapeutics
NEWTOWN, Pa., Aug. 15, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...